Clinical Trial Update: Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating EVP-0962 for safety, tolerability, and pharmacokinetics, and its effects on cerebrospinal fluid amyloid concentrations in healthy subje…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• EVP-0962 (EVP-0962)

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Mild Cognitive Impairment, Alzheimer's Disease | Phase 2 | Status: COMPLETED